Tissue irritation resolves within 24 to 48 hours in the majority of reported cases when proper site rotation and sterile technique are used
1,4 Adverse events 5% in SUSTAIN 5 8,10 AEs occurring in 5% of participants treated with Ozempic injection in SUSTAIN 5 Incidence of severe hypoglycemia was 1.5% across all placebo-controlled trials 1 Incidence of severe hypoglycemia or blood glucose-confirmed hypoglycemia (% of patients) was 8,10 : 8.3% with Ozempic 0.5 mg + basal insulin MET 10.7% with Ozempic 1 mg + basal insulin MET 5.3% with placebo + basal insulin MET Patients receiving Ozempic injection in combination with an insulin secretagogue (eg, sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia 1 Adverse events 5% in SUSTAIN FORTE 4 AEs occurring in 5% of patients receiving Ozempic injection 1 mg and 2 mg in SUSTAIN FORTE In placebo-controlled trials, the most common adverse reactions reported in 5% of patients treated with Ozempic injection are nausea, vomiting, diarrhea, abdominal pain, and constipation 1 No new safety signals were identified
In fact, insulin therapy can sometimes lead to weight gain, as it helps store excess calories in the form of fat
Acknowledgements This work was financially supported by the German Research Foundation (Collaborative Research Centre 1112, Project C02 to MSK, C05 to JL, and Z01 to NM, MSK, and BK
BBB status can be not only qualitatively (statically) but also quantitatively (dynamically) evaluated depending on the inclusion of time as a variable of interest and the attenuation or enhancement pattern following the administration of contrast agent as the nominators
BPC-157 is a synthetic peptide -- a short chain of 15 amino acids -- derived from a protein found naturally in human gastric juice
